

In the Claims

Applicant has submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by strikeouts and/or double bracketing.

Please cancel claims 1-17 and 36-41 without prejudice or disclaimer.

Please amend pending claims 18-29 and 33 as noted below.

1.-17. (Canceled)

18. (Currently Amended) A composition, comprising ~~an isolated binding peptide that selectively binds to a human MBL epitope, wherein the isolated MBL binding peptide has an~~ MBL binding CDR3 region ~~or a functional variant thereof~~ of a monoclonal antibody produced by a hybridoma cell line selected from the group consisting of hybridoma cell line_(3F8), hybridoma cell line_(2A9), and hybridoma cell line_(hMBL1.2) deposited under ATCC accession numbers HB-12621, HB-12620, and HB-12619 respectively, ~~and wherein the functional variant thereof has an MBL binding CDR3 region with a conservative substitution therein.~~

19. (Currently Amended) The composition of claim 18, wherein the ~~isolated MBL binding peptide has an~~ MBL binding CDR3₁ region ~~is or a functional variant thereof~~ of a monoclonal antibody produced by hybridoma cell line_(3F8) deposited under ATCC accession number HB-12621.

20. (Currently Amended) The composition of claim 18, wherein the ~~isolated MBL binding peptide has an~~ MBL binding CDR3₂ region ~~is or a functional variant thereof~~ of a monoclonal antibody produced by hybridoma cell line_(2A9) deposited under ATCC accession number HB-12620.

21. (Currently Amended) The composition of claim 18, wherein the ~~isolated MBL binding peptide has an~~ MBL binding CDR3₁ region ~~is or a functional variant thereof~~ of a

monoclonal antibody produced by hybridoma cell line_(hMBL1.2) deposited under ATCC accession number HB-12619.

22. (Currently Amended) The composition of claim 18 wherein the ~~isolated peptide is~~ composition comprises an intact soluble monoclonal antibody.

23. (Currently Amended) The composition of claim 18 wherein the ~~isolated peptide is~~ composition comprises a monoclonal antibody_(3F8) produced by the hybridoma cell line deposited under ATCC Accession No. HB-12621.

24. (Currently Amended) The composition of claim 18 wherein the ~~isolated peptide is~~ composition comprises a monoclonal antibody_(2A9) produced by the hybridoma cell line deposited under ATCC Accession No. HB-12620.

25. (Currently Amended) The composition of claim 18 wherein the ~~isolated peptide is~~ composition comprises a monoclonal antibody_(hMBL1.2) produced by the hybridoma cell line deposited under ATCC Accession No. HB-12619.

26. (Currently Amended) The composition of claim 18 wherein the ~~isolated peptide is~~ composition comprises a humanized monoclonal antibody.

27. (Currently Amended) The composition of claim 18 wherein the ~~isolated peptide is~~ composition comprises a monoclonal antibody fragment selected from the group consisting of an F(ab')₂ fragment, an Fd fragment, and an Fab fragment.

28. (Currently Amended) The composition of claim 18 wherein the ~~isolated peptide has~~ composition further comprises a light chain CDR2 region selected from the group consisting of a CDR2_(3F8) of a monoclonal antibody produced by hybridoma_(3F8) deposited under ATCC Accession No. HB-12621, a CDR2_(2A9) of a monoclonal antibody produced by hybridoma_(2A9) deposited under ATCC Accession No. HB-12620, and a CDR2_(hMBL1.2) of a monoclonal antibody produced by hybridoma_(hMBL1.2) deposited under ATCC Accession No. HB-12619.

29. (Currently Amended) The composition of claim 18 wherein the ~~isolated peptide has composition further comprises~~ a light chain CDR1 region selected from the group consisting of a CDR1_(3F8) of a monoclonal antibody produced by hybridoma_(3F8) deposited under ATCC Accession No. HB-12621, a CDR1_(2A9) of a monoclonal antibody produced by hybridoma_(2A9) deposited under ATCC Accession No. HB-12620, and a CDR1_(hMBL1.2) of a monoclonal antibody_(hMBL1.2) produced by hybridoma hMBL1.2 deposited under ATCC Accession No. HB-12619.

30. (Original) A hybridoma cell line deposited under ATCC Accession No. HB-12621.

31. (Original) A hybridoma cell line deposited under ATCC Accession No. HB-12620.

32. (Original) A hybridoma cell line deposited under ATCC Accession No. HB-12619.

33. (Currently Amended) The composition of claim 18, wherein the composition is a pharmaceutical composition including an effective amount of the ~~isolated MBL binding peptide~~ MBL binding CDR3 region for treating an MBL mediated disorder; and,
a pharmaceutically acceptable carrier.

34. (Original) The composition of claim 33, further comprising a drug for the treatment of an MBL mediated disorder.

35.-41. (Canceled)